ASH 2020 | Top picks in ALL from ASH 2020
Josep-Maria Ribera
• 9 Dec 2020
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, shares his highlights from ASH 2020 in the field of acute lymphoblastic leukemia (ALL). In particular, he discusses trials of novel agents in the frontline setting, including blinatumomab, inotuzumab, venetoclax, navitoclax and bortezomib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Josep-Maria Ribera, has been a speaker, participated in advisory boards and received honoraria from Pfizer, AMGEN, Shire and Ariad; has participated in clinical trials with Pfizer, AMGEN and Ariad; and has received research support from AMGEN.
